keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab glioblastoma

keyword
https://www.readbyqxmd.com/read/28726173/recurrent-glioblastomas-in-the-elderly-after-maximal-first-line-treatment-does-preserved-overall-condition-warrant-a-maximal-second-line-treatment
#1
Marc Zanello, Alexandre Roux, Renata Ursu, Sophie Peeters, Luc Bauchet, Georges Noel, Jacques Guyotat, Pierre-Jean Le Reste, Thierry Faillot, Fabien Litre, Nicolas Desse, Evelyne Emery, Antoine Petit, Johann Peltier, Jimmy Voirin, François Caire, Jean-Luc Barat, Jean-Rodolphe Vignes, Philippe Menei, Olivier Langlois, Edouard Dezamis, Antoine Carpentier, Phong Dam Hieu, Philippe Metellus, Johan Pallud
A growing literature supports maximal safe resection followed by standard combined chemoradiotherapy (i.e. maximal first-line therapy) for selected elderly glioblastoma patients. To assess the prognostic factors from recurrence in elderly glioblastoma patients treated by maximal safe resection followed by standard combined chemoradiotherapy as first-line therapy. Multicentric retrospective analysis comparing the prognosis and optimal oncological management of recurrent glioblastomas between 660 adult patients aged of < 70 years (standard group) and 117 patients aged of ≥70 years (elderly group) harboring a supratentorial glioblastoma treated by maximal first-line therapy...
July 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28711289/clinical-outcomes-in-recurrent-glioblastoma-with-bevacizumab-therapy-an-analysis-of-the-literature
#2
REVIEW
Matthew Tipping, Jens Eickhoff, H Ian Robins
Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous review (995 patients) estimated a progression free survival (PFS) on BEV of 4.2months (SD±2.1) with an overall survival (OS) after progression on BEV at 3.8months (SD±1). We endeavored to establish a more rigorous historical control, both as a benchmark for efficacy, and a prognostic tool for clinical practice...
July 12, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28702781/radiographic-patterns-of-progression-with-associated-outcomes-after-bevacizumab-therapy-in-glioblastoma-patients
#3
David Cachia, Nabil A Elshafeey, Carlos Kamiya-Matsuoka, Masumeh Hatami, Kristin D Alfaro-Munoz, Jacob J Mandel, Rivka Colen, John F DeGroot
Treatment response and survival after bevacizumab failure remains poor in patients with glioblastoma. Several recent publications examining glioblastoma patients treated with bevacizumab have described specific radiographic patterns of disease progression as correlating with outcome. This study aims to scrutinize these previously reported radiographic prognostic models in an independent data set to inspect their reproducibility and potential for clinical utility. Sixty four patients treated at MD Anderson matched predetermined inclusion criteria...
July 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28698441/-combination-therapy-with-radiation-temozolomide-and-bevacizumab-after-partial-tumor-removal-in-glioblastoma-patients-with-low-performance-status
#4
Junzo Nakao, Eiichi Ishikawa, Masahide Matsuda, Tetsuya Yamamoto, Shingo Takano, Akira Matsumura
INTRODUCTION: It is unclear whether or not bevacizumab(Bev)has a curative ability in newly diagnosed glioblastoma(GBM) patients with low Karnofsky performance status(KPS). MATERIALS AND METHODS: Four of 14 patients with newly diagnosed GBM received combination therapy with extended local radiation, temozolomide(TMZ), and Bev after partialremovalor biopsy of the tumor. RESULTS: The average patient age was 77.2 years(range 67-85)and the male-to-female ratio was 1:3...
June 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28693286/bevacizumab-as-a-last-line-treatment-for-glioblastoma-following-failure-of-radiotherapy-temozolomide-and-lomustine
#5
Katharina J Wenger, Marlies Wagner, Se-Jong You, Kea Franz, Patrick N Harter, Michael C Burger, Martin Voss, Michael W Ronellenfitsch, Emmanouil Fokas, Joachim P Steinbach, Oliver Bähr
In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at the first recurrence. Randomized clinical trials at the second or further recurrence following the failure of radiotherapy, temozolomide and lomustine, and retrospective analyses focusing on this specific cohort, are not yet available. A total of 62 patients with glioblastoma who received bevacizumab after the failure of standard care, including radiotherapy, temozolomide and lomustine, were retrospectively identified...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28678747/targeting-intercellular-adhesion-molecule-1-prolongs-survival-in-mice-bearing-bevacizumab-resistant-glioblastoma
#6
Yuji Piao, Verlene Henry, Ningyi Tiao, Soon Young Park, Juan Martinez-Ledesma, Jian Wen Dong, Veerakumar Balasubramaniyan, John F de Groot
Intercellular cell adhesion molecule 1 (ICAM-1; also known as CD54) is overexpressed in bevacizumab-resistant glioblastoma. In the present study, we tested our hypothesis that highly expressed ICAM-1 mediates glioblastoma's resistance to antiangiogenic therapy. We validated ICAM-1 overexpression in tumors resistant to antiangiogenic therapy using real-time polymerase chain reaction, immunohistochemistry, and Western blotting. We also detected ICAM1 expression in most glioma stem cells (GSCs). We investigated the mechanism of ICAM-1 overexpression after bevacizumab treatment and found that ICAM-1 protein expression was markedly increased in a time-dependent manner in GSC11 and GSC17 cells under hypoxic conditions in vitro...
June 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28678383/the-role-of-early-magnetic-resonance-imaging-in-predicting-survival-on-bevacizumab-for-recurrent-glioblastoma-results-from-a-prospective-clinical-trial-cabaret
#7
Kathryn M Field, Pramit M Phal, Greg Fitt, Christine Goh, Anna K Nowak, Mark A Rosenthal, John Simes, Elizabeth H Barnes, Kate Sawkins, Lawrence M Cher, Elizabeth J Hovey, Helen Wheeler
BACKGROUND: Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit. An early indicator of efficacy or futility may allow early discontinuation for nonresponders. This study prospectively assessed the role of early magnetic resonance imaging (eMRI) and its correlation with subsequent routine magnetic resonance imaging (MRI) results and survival. METHODS: Patients were part of a randomized phase 2 clinical trial (CABARET) comparing bevacizumab with bevacizumab plus carboplatin for recurrent glioblastoma...
July 5, 2017: Cancer
https://www.readbyqxmd.com/read/28668888/efficacy-of-combination-therapy-with-met-and-vegf-inhibitors-for-met-overexpressing-glioblastoma
#8
Takeshi Okuda, Takayuki Tasaki, Susumu Nakata, Kimihiro Yamashita, Hiromasa Yoshioka, Shuichi Izumoto, Amami Kato, Mitsugu Fujita
BACKGROUND: Glioblastoma multiforme (GBM) is a malignant brain tumor with an extremely poor prognosis. GBM tissues frequently express mesenchymal-epithelial transition factor (MET), which induces cell division, growth and migration. In addition, angiogenesis is a significant feature of GBM, attributable to the overexpression of vascular endothelial growth factor (VEGF). Although the VEGF inhibitor bevacizumab was recently highlighted as the second-line drug for GBM treatment, GBMs often recur even with bevacizumab therapy...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28667595/optimizing-bevacizumab-dosing-in-glioblastoma-less-is-more
#9
Abdulrazag Ajlan, Piia Thomas, Abdulrahman Albakr, Seema Nagpal, Lawrence Recht
Compared to traditional chemotherapies, where dose limiting toxicities represent the maximum possible dose, monoclonal antibody therapies are used at doses well below maximum tolerated dose. However, there has been little effort to ascertain whether there is a submaximal dose at which the efficacy/complication ratio is maximized. Thus, despite the general practice of using Bevacizumab (BEV) at dosages of 10 mg/kg every other week for glioma patients, there has not been much prior work examining whether the relatively high complication rates reported with this agent can be decreased by lowering the dose without impairing efficacy...
June 30, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28660172/pineal-region-glioblastoma-a-case-report-and-literature-review
#10
Hayley Beacher Stowe, C Ryan Miller, Jing Wu, Dina M Randazzo, Andrew Wenhua Ju
INTRODUCTION: Pineal region glioblastoma multiforme (GBM) is a rare disease entity with a generally poor prognosis. We present a case of a patient with an unresectable pineal region GBM treated with chemoradiation with favorable outcome. CASE BACKGROUND: A 65-year-old patient who was presented with visual symptoms was found to have a pineal region tumor on imaging. A stereotactic biopsy showed a World Health Organization Grade IV GBM, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylated, isocitrate dehydrogenase 1 and 2 wild type...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28655794/diffusion-mri-phenotypes-predict-overall-survival-benefitfrom-anti-vegf-monotherapy-in-recurrent-glioblastoma-converging-evidence-from-phase-ii-trials
#11
Benjamin M Ellingson, Elizabeth Gerstner, Marion Smits, Raymond Y Huang, Rivka R Colen, Lauren E Abrey, Dana T Aftab, Gisela M Schwab, Colin Hessel, Robert J Harris, Ararat Chakhoyan, Renske Gahrmann, Whitney B Pope, Kevin Leu, Catalina Raymond, Davis C Woodworth, John F de Groot, Patrick Y Wen, Tracy Batchelor, Martin J van den Bent, Timothy F Cloughesy
Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozantinib, or aflibercept monotherapy at first or second recurrence. These findings were validated using a separate trial comparing bevacizumab with lomustine. <br /><br />Experimental Design: Patients with recurrent GBM and diffusion MRI from the monotherapy arms of 5 separate Phase II clinical trials were included: 1) cediranib (NCT00035656); 2) bevacizumab (BRAIN Trial, AVF3708g; NCT00345163); 3) cabozantinib (XL184-201; NCT00704288); 4) aflibercept (VEGF Trap; NCT00369590); and 5) bevacizumab or lomustine (BELOB; NTR1929)...
June 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28638456/temozolomide-and-bevacizumab-induction-before-chemoradiotherapy-in-patients-with-bulky-glioblastoma-and-or-with-severe-neurological-impairment
#12
Ilan Darmon, Mony Chenda Morisse, Alexandre Coutte, Marie Blonski, Emilie Le Rhun, Luc Taillandier, Diana Bello Roufai, Christine Desenclos, Stéphanie Trudel, Jean-Christophe Faivre, Nicolas Blanchard, Bruno Chauffert, Mathieu Boone
Background. New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy. Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid impact on tumor-related brain edema in recurrent GB. The present study reports the feasibility and efficacy of an induction treatment with TMZ and BEV to alleviate the initial neurological impairment and/or to reduce the tumor volume before a delayed chemoradiotherapy...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28634311/-bevacizumab-related-hyperintense-lesions-on-diffusion-weighted-imaging-at-different-locations-in-a-patient-with-malignant-glioma
#13
Shinya Oshiro, Naoki Wakuta, Shinichi Kawai, Koichi Miki, Yutaka Shigemori
We report the case of a 60-year-old man who first presented with transient difficulty of word recall. Subsequent MRI revealed an invasive brain tumor in the left frontal lobe. The patient underwent open biopsy, and diffuse astrocytoma(WHO grade II)was diagnosed. However, the malignant potential of this tumor was not particularly low because of a few enhancement on preoperative evaluation, and radiation therapy was initially performed. Four months after ending irradiation, temozolomide treatment was introduced for tumor regrowth...
June 2017: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/28631191/effect-of-angiotensin-system-inhibitors-on-survival-in-newly-diagnosed-glioma-patients-and-recurrent-glioblastoma-patients-receiving-chemotherapy-and-or-bevacizumab
#14
Victor A Levin, James Chan, Meenal Datta, Jennie L Yee, Rakesh K Jain
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM)...
June 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28627960/lack-of-functional-normalisation-of-tumour-vessels-following-anti-angiogenic-therapy-in-glioblastoma
#15
Nina Obad, Heidi Espedal, Radovan Jirik, Per Oystein Sakariassen, Cecilie Brekke Rygh, Morten Lund-Johansen, Torfinn Taxt, Simone P Niclou, Rolf Bjerkvig, Olivier Keunen
Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known...
January 1, 2017: Journal of Cerebral Blood Flow and Metabolism
https://www.readbyqxmd.com/read/28616662/perifosine-enhances-bevacizumab-induced-apoptosis-and-therapeutic-efficacy-by-targeting-pi3k-akt-pathway-in-a-glioblastoma-heterotopic-model
#16
Sara Ramezani, Nasim Vousooghi, Fatemeh Ramezani Kapourchali, Mohammad Taghi Joghataei
Bevacizumab (BVZ) as an antiangiogenesis therapy leads to a transient therapeutic efficacy in high-grade glioma. However, the proapoptotic potential of BVZ has not been well elucidated, yet. There is also a tumor resistance to BVZ that is linked to post-treatment metalloproteinases and AKT activities. Herein, the association between therapeutic efficacy and putative proapoptotic activity of low-dose BVZ either alone or in combination with a specific inhibitor of AKT called perifosine (PRF), in a glioma model was investigated...
June 14, 2017: Apoptosis: An International Journal on Programmed Cell Death
https://www.readbyqxmd.com/read/28597184/epithelial-membrane-protein-2-emp2-promotes-angiogenesis-in-glioblastoma-multiforme
#17
Yu Qin, Masamichi Takahashi, Kristopher Sheets, Horacio Soto, Jessica Tsui, Panayiotis Pelargos, Joseph P Antonios, Noriyuki Kasahara, Isaac Yang, Robert M Prins, Jonathan Braun, Lynn K Gordon, Madhuri Wadehra
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor and is associated with an extremely poor clinical prognosis. One pathologic hallmark of GBM is excessive vascularization with abnormal blood vessels. Extensive investigation of anti-angiogenic therapy as a treatment for recurrent GBM has been performed. Bevacizumab, a monoclonal anti-vascular endothelial growth factor A (VEGF-A), suggests a progression-free survival benefit but no overall survival benefit. Developing novel anti-angiogenic therapies are urgently needed in controlling GBM growth...
June 9, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28594901/detection-of-human-cytomegalovirus-in-glioblastoma-among-taiwanese-subjects
#18
Ching-Fen Yang, Hsiang-Ling Ho, Shih-Chieh Lin, Chih-Yi Hsu, Donald Ming-Tak Ho
The relationship between human cytomegalovirus (HCMV) and glioblastoma (GBM) has been debated for more than a decade. We investigated the presence of HCMV genes, RNA and protein in GBMs and their relationships with tumor progression. Results of quantitative PCR for HCMV UL73, nested PCR for HCMV UL144, in situ hybridization (ISH) for RNA transcript, and immunohistochemistry (IHC) for protein expression and their relationship to the prognosis of 116 patients with GBM were evaluated. Nine (7.8%) cases revealed a low concentration of HCMV UL73, and only 2 of the 9 (1...
2017: PloS One
https://www.readbyqxmd.com/read/28562358/a-phase-2-study-of-the-first-imipridone-onc201-a-selective-drd2-antagonist-for-oncology-administered-every-three-weeks-in-recurrent-glioblastoma
#19
Isabel Arrillaga-Romany, Andrew S Chi, Joshua E Allen, Wolfgang Oster, Patrick Y Wen, Tracy T Batchelor
ONC201 is an oral, small molecule selective antagonist of the G protein-coupled receptor DRD2 that causes p53-independent apoptosis in tumor cells via integrated stress response activation and Akt/ERK inactivation. We performed a Phase II study that enrolled 17 patients with recurrent, bevacizumab-naïve, IDH1/2 WT glioblastoma who received 625mg ONC201 every three weeks. Median OS was 41.6 weeks with OS6 of 71% and OS9 of 53%. Seven of 17 patients are alive. PFS6 was 11.8% with two patients remaining on study who continue to receive ONC201 for >12 months...
May 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28555422/ischemic-stroke-and-intracranial-hemorrhage-in-patients-with-recurrent-glioblastoma-multiforme-treated-with-bevacizumab
#20
Timo A Auer, Mirjam Renovanz, Federico Marini, Marc A Brockmann, Yasemin Tanyildizi
Bevacizumab (BVZ), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been suspected to increase the incidence of ischemic stroke (IS) and intracranial hemorrhage (ICH) in GBM patients. Intracranial vascular events, such as IS and ICH, were retrospectively analyzed in 364 MRI scans of 82 patients with recurrent GBM (1st/2nd/3rd relapse). Out of these 82 patients, 40 were treated with BVZ (178 scans) in addition to basic treatment, whereas 42 patients matching for age and gender received basic treatment (186 scans)...
May 29, 2017: Journal of Neuro-oncology
keyword
keyword
80321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"